Yiling Pharmaceutical (002603.SZ): Clinical trial application for LB220-D08 extended-release tablets approved

Zhitong Finance APP News, Yiling Pharmaceutical (002603.SZ) announced that recently, the company received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and LB220-D08 sustained-release tablets have been approved to conduct clinical trials for atypical hemolytic uremic syndrome (aHUS).